SynthesisBMC cancer2021

How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review.

Mikyung Kelly Seo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.